ARCHIVES

Tafinlar Subgroup Data Shows Median OS of 20 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

News Analysis: Filing Will Ignite Complex Litigation Costing Millions, With Uncertain Rewards

March 9, 2012

Combine Phase 1-2, Abolish DRG, Slash Indirect Costs, Garb Tells Congress

November 27, 1981

GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile

August 30, 2013

NCI Advisory Group, Other Cancer Meetings

February 28, 1986

In Brief: Hong to Retire After 30 Years at MD Anderson

February 14, 2014

Cancer Training Programs Fairing Fairley Well

December 1, 1989